BriaCell Therapeutics Corp. (BCTX) Income from Continuing Operations (2021 - 2026)

BriaCell Therapeutics has reported Income from Continuing Operations for 6 years, with the latest figure at 7431205.0 in Q2 2026.

• Quarterly Income from Continuing Operations fell 17.24% year-over-year to 7431205.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was 31657513.0 (down 29.7% YoY) and the FY2025 annual result came in at 51414565.0, down 0.66% from the prior year.
• Income from Continuing Operations was little changed at 7431205.0 in Q2 2026 per BCTX's latest filing, from 7426128.0 in the prior quarter.
• Over five years, Income from Continuing Operations peaked at 3865209.0 in Q1 2022 and troughed at 9747851.0 in Q1 2024.
• A 5-year average of 6883623.56 and a median of 7274369.5 in 2025 frame the typical range for Income from Continuing Operations.
• The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations tumbled 3672.85% in 2022, then surged 37.98% in 2024.
• Over 5 years, Income from Continuing Operations stood at 5320398.0 in 2022, then plunged by 56.91% to 8348213.0 in 2023, then surged by 37.98% to 5177892.0 in 2024, then slumped by 60.63% to 8317461.0 in 2025, then increased by 10.66% to 7431205.0 in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 7431205.0, 7426128.0, and 8317461.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.